Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Recommendation of "Reduce" from Analysts

Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) has been given a consensus recommendation of "Reduce" by the twelve analysts that are currently covering the stock, MarketBeat reports. Four research analysts have rated the stock with a sell rating, seven have given a hold rating and one has issued a buy rating on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $8.20.

FULC has been the topic of several research reports. Citigroup downgraded Fulcrum Therapeutics from an "underperform" rating to an "underweight" rating in a research report on Tuesday, June 2nd. JPMorgan Chase & Co. lowered shares of Fulcrum Therapeutics from an "overweight" rating to an "underweight" rating in a report on Wednesday, June 3rd. Piper Sandler lowered shares of Fulcrum Therapeutics from an "overweight" rating to a "neutral" rating and set a $3.00 target price for the company. in a report on Tuesday, June 2nd. Stifel Nicolaus cut shares of Fulcrum Therapeutics from a "buy" rating to a "hold" rating and set a $3.00 target price for the company. in a research report on Tuesday, June 2nd. Finally, HC Wainwright lowered shares of Fulcrum Therapeutics from a "buy" rating to a "neutral" rating and set a $3.00 target price on the stock. in a research note on Tuesday, June 2nd.

Insider Activity

In related news, Director Alan Ezekowitz sold 18,000 shares of the business's stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $3.65, for a total value of $65,700.00. Following the sale, the director directly owned 10,927 shares in the company, valued at approximately $39,883.55. The trade was a 62.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 7.30% of the company's stock.

Institutional Investors Weigh In On Fulcrum Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the company. Suvretta Capital Management LLC increased its stake in Fulcrum Therapeutics by 21.9% during the fourth quarter. Suvretta Capital Management LLC now owns 6,561,111 shares of the company's stock worth $74,206,000 after purchasing an additional 1,180,111 shares during the period. Nantahala Capital Management LLC lifted its position in shares of Fulcrum Therapeutics by 8.9% during the 3rd quarter. Nantahala Capital Management LLC now owns 4,670,784 shares of the company's stock worth $42,971,000 after buying an additional 382,485 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its stake in Fulcrum Therapeutics by 53.0% in the second quarter. Adage Capital Partners GP L.L.C. now owns 4,589,000 shares of the company's stock valued at $31,572,000 after acquiring an additional 1,589,000 shares in the last quarter. Braidwell LP boosted its position in shares of Fulcrum Therapeutics by 1,294.7% in the 4th quarter. Braidwell LP now owns 3,061,222 shares of the company's stock valued at $34,622,000 after purchasing an additional 2,841,734 shares during the period. Finally, Siren L.L.C. boosted its holdings in shares of Fulcrum Therapeutics by 20.5% in the first quarter. Siren L.L.C. now owns 2,350,000 shares of the company's stock valued at $18,024,000 after acquiring an additional 400,000 shares during the period. Hedge funds and other institutional investors own 89.83% of the company's stock.

Fulcrum Therapeutics Stock Up 0.3%

Shares of NASDAQ FULC opened at $3.78 on Friday. The firm has a market cap of $288.41 million, a price-to-earnings ratio of -3.12 and a beta of 3.05. The company's 50-day simple moving average is $3.75 and its 200-day simple moving average is $6.72. Fulcrum Therapeutics has a 52-week low of $2.83 and a 52-week high of $15.74.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.10). Equities research analysts anticipate that Fulcrum Therapeutics will post -0.67 EPS for the current fiscal year.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company's core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum's most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source